Liquidia Earnings Call Transcripts
Fiscal Year 2026
-
The meeting confirmed a quorum, introduced directors and officers, and approved all proposals, including director elections, auditor ratification, and executive compensation. No shareholder questions were raised, and forward-looking risks were referenced.
-
YUTREPIA achieved rapid market penetration and strong revenue growth, with expansion into new indications and a robust clinical pipeline. The company is scaling its sales force, investing in manufacturing, and maintaining financial discipline while preparing for future market and legal developments.
-
YUTREPIA's launch has driven rapid revenue growth and profitability, with expansion into PAH and PH-ILD markets supported by robust clinical data and ongoing studies. The pipeline, including L606, targets further innovation, while strong physician relationships and reinvestment in R&D underpin future growth.
-
YUTREPIA's launch has exceeded expectations, achieving rapid revenue growth, expanding market share, and maintaining strong financial discipline. The company is investing in clinical studies, sales force expansion, and manufacturing to capture a $3–5 billion market opportunity, with a $1 billion revenue target for 2027.
-
YUTREPIA drove 44% sequential sales growth and tripled EBITDA in Q1 2026, achieving over $500M annualized run rate. Market share in inhaled prostacyclins neared 23%, with robust expansion in both PAH and PH-ILD segments. Management maintains confidence in reaching $1B revenue by 2027.
-
YUTREPIA has rapidly gained market share with strong patient uptake, robust financial performance, and broad prescriber adoption. Expansion of the sales force, new clinical studies, and a focus on displacing oral therapies are expected to drive growth toward a $1 billion revenue target by 2027. Legal and competitive dynamics remain important watchpoints.
-
Profitability was achieved in the first quarter of launch, with rapid market share gains and strong cash flow. Yutrepia and L606 are driving growth through new indications and clinical studies, with plans to double manufacturing capacity and expand globally.
Fiscal Year 2025
-
YUTREPIA achieved rapid commercial success, driving $148.3M in 2025 sales and expanding market share to 17% in Q4. With robust patient growth, high prescriber adoption, and new clinical programs, the company targets $1B revenue by 2027, funded by strong cash flow.
-
YUTREPIA’s strong launch drove rapid revenue growth, high patient uptake, and early profitability, supported by clinical data showing superior tolerability and efficacy. Management is confident in their legal position and is preparing for all outcomes, while advancing pipeline programs and maintaining financial discipline.
-
Strong early launch performance with rapid revenue growth and profitability, driven by differentiated inhaled treprostinil products and expanding access. Clinical data supports higher dosing and improved patient outcomes, while new studies and next-generation products target broader markets. Awaiting key patent litigation outcome but prepared for all scenarios.
-
YUTREPIA's launch drove $51.7M in Q3 sales, rapid patient uptake, and positive adjusted EBITDA, with 85% referral-to-start conversion and broad payer access. Litigation risk remains, but market momentum and clinical expansion support strong future growth.
-
Yutrepia is rapidly gaining traction as a best-in-class inhaled treprostinil for PAH and PH-ILD, with strong tolerability and high-dose titration. L606, a twice-daily liposomal formulation, shows promising safety and efficacy, with a global phase III trial underway and broad regulatory alignment.
-
YUTREPIA's launch surpassed expectations with strong early uptake, broad patient reach, and positive physician feedback. Market expansion in PH-ILD and PAH is underway, supported by robust payer access, clinical data, and a disciplined financial approach. Awaiting key patent decision and advancing pipeline assets.
-
YUTREPIA's launch exceeded expectations with rapid adoption, strong financial results, and broad prescriber engagement. Expanded payer contracts, robust clinical data, and a solid cash position set the stage for continued growth and manufacturing expansion.
-
YUTREPIA launched for PAH and PH-ILD with rapid patient access, parity pricing, and robust supply. Differentiated by PRINT technology, it targets significant market share and profitability within a year, while expanding its pipeline and defending its IP position.
-
YUTREPIA has received FDA approval for PAH and PH-ILD, supported by robust clinical data and proprietary PRINT technology. The commercial launch is fully underway with broad access initiatives, competitive pricing, and strong financial backing, aiming for profitability within a year.
-
YUTREPIA is nearing FDA approval, supported by robust clinical data and a comprehensive launch strategy targeting the large, underpenetrated PH-ILD and PAH markets. Legal challenges persist, but recent wins and strong payer engagement position the product for broad access and rapid uptake.
-
YUTREPIA is nearing potential approval with no current legal barriers, supported by strong clinical data and robust launch preparations. Q1 2025 saw a wider net loss due to increased commercialization spending, while revenue remained stable. Market opportunity is significant, with a $4 billion addressable market.
-
YUTREPIA is set for a near-term launch in PAH and PH-ILD, with strong differentiation from competitors due to its PRINT technology and robust market preparation. The company expects broad payer access, rapid commercialization, and profitability within a year of launch, while advancing its L606 pipeline and expanding clinical data presentations.
-
Yutrepia, a PRINT-based inhaled treprostinil, is positioned for a 2025 launch targeting PAH and PH-ILD markets, offering higher dosing, improved tolerability, and rapid dose escalation compared to current therapies. Legal and regulatory pathways are clear, and the company is financially prepared for commercialization.
Fiscal Year 2024
-
2024 saw a net loss of $130.4M on $14M revenue, with higher R&D and administrative costs as the company prepares for YUTREPIA's anticipated launch in PAH and PH-ILD after May 2025. Expanded financing and strong ASCEND trial data support a positive outlook.
-
Yutrepia is poised for a potential mid-2025 launch pending legal and regulatory outcomes, with strong commercial readiness and a differentiated clinical profile. L606 advances toward a global pivotal study, and robust cash reserves support both initiatives.
-
Final FDA approval for YUTREPIA is expected after Tyvaso DPI exclusivity expires in May 2025, with legal and clinical milestones advancing. Q3 revenue grew 19% year-over-year, and the company ended the quarter with $204.4 million in cash, supporting launch and R&D plans.
-
YUTREPIA is set for a May 2025 launch in large, underserved PH-ILD and PAH markets, with strong commercial and financial preparation. Ongoing litigation and patent challenges are not expected to impede launch, while a global pivotal trial for L606 is planned for late 2024.
-
Yutrepia, leveraging PRINT technology, is set for a Q2 2025 launch in PAH and PH-ILD, pending exclusivity expiration. Market opportunities are significant, especially in PH-ILD, with a robust sales force and supply chain in place. Ongoing litigation is not expected to delay launch.
-
Awaiting FDA approval for YUTREPIA, with teams ready for launch and strong financial positioning. Q2 revenue declined year-over-year, but cash reserves remain robust to support ongoing clinical programs and potential product launches.
-
YUTREPIA is poised for imminent FDA approval in PAH and PH-ILD, following favorable legal outcomes and strong clinical data. The company is fully prepared for launch, with a robust sales force and manufacturing readiness, while advancing L606, a next-generation formulation, into phase III trials.